Stockreport

NeuroPace Reports Fourth Quarter and Full Year 2025 Financial Results and Reiterates 2026 Outlook [Yahoo! Finance]

Neuropace, Inc.  (NPCE) 
PDF -- Reiterates previously issued 2026 guidance assuming 20% to 22% growth in core RNS ® revenue from existing indications, excluding any contribution from idiopathic gen [Read more]